CytomX Therapeutics Inc

For the period ended Dec 31, 2024. Filed Mar 6, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 6, 2025

CTMX$1.98-9.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Stockholders’ Deficit

	Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Capital	Income/(Loss)	Deficit	Deficit
Balance at December 31, 2022	66,228,046	$1	$637,117	$10	$(722,879)	$(85,751)
Exercise of stock options and release of RSUs	675,864	—	26	—	—	26
Issuance of common stock under the Employee Stock Purchase Plan	406,928	—	535	—	—	535
Issuance of pre-funded warrants and warrants, net of issuance cost	—	—	29,669	—	—	29,669
Stock-based compensation	—	—	8,558	—	—	8,558
Other comprehensive income	—	—	—	85	—	85
Net loss	—	—	—	—	(569)	(569)
Balance at December 31, 2023	67,310,838	1	675,905	95	(723,448)	(47,447)
Exercise of stock options and release of RSUs	980,552	—	209	—	—	209
Issuance of common stock under the Employee Stock Purchase Plan	383,346	—	404	—	—	404
Issuance of common stock under the Open Market Sale Agreement, net of issuance cost	3,925,202	—	6,909	—	—	6,909
Exercise of pre-funded warrants	7,499,951	—	—	—	—	—
Stock-based compensation	—	—	7,668	—	—	7,668
Other comprehensive income	—	—	—	(68)	—	(68)
Net income	—	—	—	—	31,869	31,869
Balance at December 31, 2024	80,099,889	$1	$691,095	$27	$(691,579)	$(456)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.